We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

58 hedge funds and large institutions have $110M invested in VYNE Therapeutics in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 12

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

0.01% more ownership

Funds ownership: 1.06% → 1.06% (+0.01%)

2% less funds holding

Funds holding: 59 → 58 (-1)

21% less capital invested

Capital invested by funds: $139M → $110M (-$29.4M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
58
Holders Change
-1
Holders Change %
-1.69%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
5
Increased
30
Reduced
12
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
MP
Mangrove Partners
Connecticut
+$2.01M
2
BlackRock
BlackRock
New York
+$1.94M
3
State Street
State Street
Massachusetts
+$522K
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$445K
5
Renaissance Technologies
Renaissance Technologies
New York
+$430K

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$2.22M
2
SIM
Spark Investment Management
New York
-$394K
3
AIM
Alambic Investment Management
California
-$352K
4
Morgan Stanley
Morgan Stanley
New York
-$242K
5
First Manhattan
First Manhattan
New York
-$211K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$24M – – –
First Manhattan
2
First Manhattan
New York
$13.3M -$211K -427 -1%
GPP
3
Great Point Partners
Connecticut
$10.4M -$2.22M -4,488 -16%
VP
4
venBio Partners
California
$8.76M – – –
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$8.68M -$54.4K -110 -0.5%
BlackRock
6
BlackRock
New York
$5.47M +$1.94M +3,917 +45%
MP
7
Mangrove Partners
Connecticut
$5.11M +$2.01M +4,058 +52%
BBA
8
Baker Bros. Advisors
New York
$4.19M – – –
O
9
OrbiMed
New York
$4.04M +$274K +553 +6%
DCM
10
DAFNA Capital Management
California
$3.59M – – –
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$3.58M -$14.8K -30 -0.4%
JP Morgan Chase
12
JP Morgan Chase
New York
$3.36M -$176K -356 -4%
Vanguard Group
13
Vanguard Group
Pennsylvania
$3.35M +$158K +320 +4%
State Street
14
State Street
Massachusetts
$1.25M +$522K +1,055 +57%
DM
15
Deerfield Management
New York
$1.19M – – –
BCM
16
Bridgeway Capital Management
Texas
$789K – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$740K +$237K +479 +39%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$684K +$63.3K +128 +9%
Renaissance Technologies
19
Renaissance Technologies
New York
$659K +$430K +868 +132%
Northern Trust
20
Northern Trust
Illinois
$648K +$56.9K +115 +8%
Bank of America
21
Bank of America
North Carolina
$464K +$265K +535 +99%
OAM
22
Oxford Asset Management
United Kingdom
$412K +$238K +481 +101%
PPA
23
Parametric Portfolio Associates
Washington
$401K +$195K +395 +74%
Assenagon Asset Management
24
Assenagon Asset Management
Luxembourg
$388K +$445K +900 New
Charles Schwab
25
Charles Schwab
California
$321K +$86.1K +174 +31%
1
2 3

VYNE Hedge Fund Activity: Q2 2019 in Review

58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2019, worth a combined $110M — down 21% from $139M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VYNE positions and 4 closed out — a net gain of 1 holder — while 30 added to existing stakes and 12 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $2.01M. The largest seller was Great Point Partners, cutting an estimated $2.22M.

  • 58 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2019, down from 59 in Q1 2019.
  • Funds reported $110M of VYNE Therapeutics stock for Q2 2019, down 21% quarter-over-quarter.
  • 5 funds opened new VYNE Therapeutics positions in Q2 2019 and 4 closed out, a net change of +1 holder.
  • The largest VYNE Therapeutics buyer in Q2 2019 was Mangrove Partners, an estimated $2.01M added.
  • The largest VYNE Therapeutics seller in Q2 2019 was Great Point Partners, an estimated $2.22M sold.

Based on aggregated 13F filings for Q2 2019.